Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: A randomized phase III non-inferiority trial (SAKK 41/06)

Annals of Oncology

Volumn 26, Issue 4, 2015, Pages 709-714

  Koeberle, Dieter ^a,o   Betticher, D C ^b   von Moos, R ^c   Dietrich, D ^d   Brauchli, P ^d   Baertschi, D ^d   Matter, K ^e   Winterhalder, R ^f   Borner, M ^c   Anchisi, S ^g   Moosmann, P ^h   Kollar, A ⁱ   Saletti, P ^j   Roth, A ^k   Frueh, M ^a   Kueng, M ^b   Popescu, R A ^l   Schacher, S ^m   Hess, V ⁿ   Herrmann, R ⁿ  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b Hopital Cantonal de Fribourg   (Switzerland)

^c Kantonsspital Chur ^*  (Switzerland)

^d SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^e Head European Center of Pharmaceutical Medicine (ECPM) Research   (Switzerland)

^f LUZERNER KANTONSSPITAL   (Switzerland)

^g Hopital de Sion   (Switzerland)

^h CANTONAL HOSPITAL AARAU   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^k HCUG   (Switzerland)

^l KLINIK HIRSLANDEN   (Switzerland)

^m CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

ⁿ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^o St Claraspital AG   (Switzerland)

more..

Author keywords

Bevacizumab; Maintenance therapy; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FLUOROURACIL; FOLINIC ACID; PLATINUM COMPLEX;

ADULT; ARTERY THROMBOSIS; ARTICLE; BLEEDING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFICACY; DRUG FATALITY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SWITZERLAND; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84926475781     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv011     Document Type: Article

References (16)

1. Berry SR, Cosby R, Asmis TR et al. Randomized controlled trials (RCTs) examining continuous (CS) versus intermittent strategies (IS) of delivering systemic treatment (Tx) for untreated metastatic colorectal cancer (mCRC): a meta-analysis from the Cancer Care Ontario program in evidence-based care (abstract). J Clin Oncol 2013; 31 (suppl; abstr 3534). http://meetinglibrary.asco.org/content/111397-132 (12 December 2013, date last accessed).
2. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
3. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
4. Tebbutt NC, Wilson K, Gebski VJ et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-3198.
5. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
6. Bennouna J, Sastra J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14(1): 29-37.
7. Díaz-Rubio E, Gómez-España A, Massutí B et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012; 17(1): 15-25.
8. Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and metaanalysis, with emphasis on chemotherapy subgroups. BMC Cancer 2012; 12: 89. [epub ahead of print 13 March 2012]. doi: 10.1186/1471-2407-12-89.
9. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27: 5727-5733.
10. Adams R, Meade A, Saymour M et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomized phase 3 MRC COIN trial. Lancet Oncol 2011; 12: 642-653.
11. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007; 25(29): 4562-4568.
12. Miles D, Harbeck N, Escudier B et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011; 29(1): 83-88.
13. Grusenmeyer PA, Wong YN. Interpreting the economic literature in oncology. J Clin Oncol 2007; 25(2): 196-202.
14. Tappenden P, Chilcott J, Ward S et al. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer 2006; 42(17): 2867-2875.
15. Koopman M, Simkens L, Ten Tije AJ et al. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2013; 31 (suppl; abstr 3502). http://meetinglibrary.asco.org/content/115023-132 (12 December 2013, date last accessed).
16. Arnold D, Graeven U, Lerchenmuller CA et al. Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (BEV) alone, or no treatment following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): a phase III non-inferiority trial (AIO KRK 0207). J Clin Oncol 2014; 32 (suppl; abstr 3503). http://meetinglibrary.asco.org/content/133066-144 (16 July 2014, date last accessed).